No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMGN240719P295000
- 0.07
- -0.12-63.16%
15min DelayTrading Jul 16 09:35 ET
0.07High0.07Low
0.07Open0.19Pre Close3 Volume1.34K Open Interest295.00Strike Price21.00Turnover48.81%IV11.18%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type-0.0058Delta0.0010Gamma1277.19Leverage Ratio-0.0242Theta-0.0002Rho-7.38Eff Leverage0.0054Vega
Intraday
- 5D
- Daily
News
Unpacking the Latest Options Trading Trends in Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 18 unusual trades.Delving into the details, we found 22% of traders
A Closer Look at Amgen's Options Market Dynamics
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Unusual Options Activity: CEG, SIRI and Others Attract Market Bets, CEG V/OI Ratio Reaches 124.3
EST Jul 15th Afternoon Delivery - In the last two hours of trading, 4 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $375
Jefferies analyst Michael Yee maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $375.According to TipRanks data, the analyst has a success rate of 45.4% and a total
Comments
$Amgen(AMGN.US$ 🚨
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
4
» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
16
I hate these days. I know it's investing & I'm long with my bets, but I have better, more exciting days when I don't see a lot of red. Sucks. And, I was terminated from my job in April & having a hard time getting unemployment. I was a 1099 contractor on that job & the department of labor doesn't know how to process my claim. This is making me low on hard cash & I'm going to have to sell a position or 2, and I DO NOT WANT TO DO THAT, especially with $Esperion Therapeutics (ESPR.US)$. I read...
7
3
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Read more